信息服务(III)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

III 信息服务

已收盘 02-27 16:00:00 EST

4.81

+0.03

+0.63%

盘后4.85

+0.04+0.83%

19:05 EST

最高4.84	最低4.61	成交量59.72万
今开4.71	昨收4.78	日振幅4.81%
总市值2.30亿	流通市值1.65亿	总股本4,788万
成交额286.71万	换手率1.74%	流通股本3,423万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"III","market":"US","secType":"STK","nameCN":"信息服务","latestPrice":4.81,"timestamp":1772226000000,"preClose":4.78,"halted":0,"volume":597222,"hourTrading":{"tag":"盘后","latestPrice":4.85,"preClose":4.81,"latestTime":"19:05 EST","volume":51166,"amount":246167.9304,"timestamp":1772237125759,"change":0.04,"changeRate":0.008316,"amplitude":0.008316},"delay":0,"changeRate":0.006276150627614929,"floatShares":34233044,"shares":47884104,"eps":0.190275,"marketStatus":"已收盘","change":0.03,"latestTime":"02-27 16:00:00 EST","open":4.71,"high":4.84,"low":4.61,"amount":2867122.773441,"amplitude":0.048117,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.190275,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1772442000000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1171256400000,"exchange":"NASDAQ","adjPreClose":4.78,"dividendRate":0.037422,"preHourTrading":{"tag":"盘前","latestPrice":4.91,"preClose":4.78,"latestTime":"08:52 EST","volume":15,"amount":73.65,"timestamp":1772200352981,"change":0.13,"changeRate":0.027197,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":4.85,"preClose":4.81,"latestTime":"19:05 EST","volume":51166,"amount":246167.9304,"timestamp":1772237125759,"change":0.04,"changeRate":0.008316,"amplitude":0.008316},"volumeRatio":2.002582,"impliedVol":1.313,"impliedVolPercentile":0.7968},"requestUrl":"/m/hq/s/III","defaultTab":"news","newsList":[{"id":"2614289542","title":"iza-bren公告III期结果；君实生物等药企发布业绩快报 | 健讯Daily","url":"https://stock-news.laohu8.com/highlight/detail?id=2614289542","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614289542?lang=zh_cn&edition=full","pubTime":"2026-02-28 08:06","pubTimestamp":1772237206,"startTime":"0","endTime":"0","summary":"国家药监局：2025年共收到创新医疗器械特别审批申请457项近日，国家药监局发布2025年度创新医疗器械等产品注册审批情况。2025年，国家药监局按照《创新医疗器械特别审查程序》《医疗器械优先审批程序》继续做好相关产品的审查工作，共收到创新医疗器械特别审批申请457项，其中104项获准进入创新医疗器械特别审查程序；收到优先申请38项，其中26项获准优先审批。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602283657320729.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602283657320729.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK1515","III","688180","BK4134","01877","BK0239","BK1583"],"gpt_icon":0},{"id":"2614882728","title":"港股异动 | 基石药业-B(02616)尾盘涨超8% 舒格利单抗III期非小细胞肺癌新适应症获英国MHRA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2614882728","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614882728?lang=zh_cn&edition=full","pubTime":"2026-02-27 15:54","pubTimestamp":1772178879,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，基石药业-B尾盘涨超8%，截至发稿，涨6.73%，报6.66港元，成交额9312.3万港元。消息面上，基石药业此前宣布，舒格利单抗的新适应症申请已获英国MHRA批准单药用于治疗肿瘤细胞PD-L1表达≥1%、无表皮生长因子受体敏感突变或ALK、ROS1基因组变异、在含铂放化疗后未出现疾病进展的、不可切除的III期NSCLC成人患者。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1408123.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","02616","BK4134","BK1574","VT","BK1161","III","VXUS","BK4585"],"gpt_icon":0},{"id":"2614062136","title":"诺诚健华新型BCL2抑制剂Mesutoclax联合奥布替尼一线治疗CLL/SLL的注册性III期临床试验完成患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2614062136","media":"人民财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614062136?lang=zh_cn&edition=full","pubTime":"2026-02-26 10:40","pubTimestamp":1772073636,"startTime":"0","endTime":"0","summary":"人民财讯2月26日电，诺诚健华2月26日宣布，公司自主研发的新型BCL2抑制剂mesutoclax（ICP-248）联合BTK抑制剂奥布替尼一线治疗慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（CLL/SLL）的注册性III期临床试验已经完成患者入组。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602263655089844.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","BK4134","BK1161","III","688428","09969","BK0239"],"gpt_icon":0},{"id":"2614670859","title":"瞄准数字资产与AI赛道，Dune Acquisition III递交1.5亿美元SPAC IPO申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2614670859","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614670859?lang=zh_cn&edition=full","pubTime":"2026-02-25 14:52","pubTimestamp":1772002329,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，专注于数字资产、体育娱乐、软件即服务及人工智能领域的特殊目的收购公司Dune Acquisition III，于周二向美国证券交易委员会递交文件，计划通过首次公开募股筹资至多1.5亿美元。Dune Acquisition III由首席执行官兼董事长Carter Glatt领导，他曾任GTY公司企业发展主管兼高级副总裁。管理层的过往SPAC项目包括：于2023年上市并完成与氢气供应商Global Gas业务合并的Dune Acquisition，以及于2025年上市的Dune Acquisition II。Dune Acquisition III已于2025年11月6日以保密方式递交申请。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1407059.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4134","DUNEU","III"],"gpt_icon":0},{"id":"2614777939","title":"港股异动 | 基石药业-B(02616)再涨超6% 月内涨超25% 舒格利单抗III期NSCLC获英国正式批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2614777939","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614777939?lang=zh_cn&edition=full","pubTime":"2026-02-25 14:04","pubTimestamp":1771999477,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，基石药业-B再涨超6%，月内累计涨幅已超25%。消息面上，2月23日，基石药业宣布，其PD-L1抗体舒格利单抗针对III期非小细胞肺癌的新适应症，已正式取得英国药品和医疗保健用品管理局的批准。此外，基石药业核心资产CS2009用于晚期实体瘤的II期临床试验IND申请近期获得FDA批准。CS2009用于晚期实体瘤的II期新药临床试验申请获美国食品药品监督管理局批准，标志着这一创新免疫疗法的全球开发取得重要进展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1407038.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02616","BK4588","BK4134","VXUS","BK1161","BK4585","III","BK1574","VT"],"gpt_icon":0},{"id":"2613750586","title":"港股异动 | 基石药业-B(02616)涨超5% 舒格利单抗III期非小细胞肺癌新适应症获英国MHRA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2613750586","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613750586?lang=zh_cn&edition=full","pubTime":"2026-02-24 10:30","pubTimestamp":1771900210,"startTime":"0","endTime":"0","summary":"消息面上，基石药业昨日公布，舒格利单抗的新适应症申请已获英国药品和医疗保健用品管理局批准单药用于治疗肿瘤细胞PD-L1表达≥1%、无表皮生长因数受体敏感突变或ALK、ROS1基因组变异、在含铂放化疗后未出现疾病进展的、不可切除的III期小细胞肺癌成人患者。继欧盟委员会批准后，舒格利单抗III期NSCLC新适应症再获英国MHRA批准，这是该产品在英国获得的第二个适应症批准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1406514.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02616","III","BK1574","BK4585","VT","BK4134","VXUS","BK4588"],"gpt_icon":0},{"id":"2613820071","title":"百利天恒(688506.SH)：iza-bren(EGFR×HER3双抗ADC)用于局部晚期或转移性三阴乳腺癌III期临试期中分析达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2613820071","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613820071?lang=zh_cn&edition=full","pubTime":"2026-02-23 16:56","pubTimestamp":1771836964,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百利天恒 披露公告，关于iza-bren用于局部晚期或转移性三阴乳腺癌III期临床试验的期中分析达到主要终点的事项，该III期临床研究独立数据监查委员会，在预设的期中分析中，建议：“基于现有的分析结果，与监管沟通提前申报，同时继续对受试者进行随访”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1406323.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4231","BK4080","BK0239","688506","BK4134","02615","III","ADC","91194"],"gpt_icon":0},{"id":"2613027209","title":"基石药业-B(02616)：舒格利单抗III期小细胞肺癌新适应症获英国MHRA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2613027209","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613027209?lang=zh_cn&edition=full","pubTime":"2026-02-23 08:17","pubTimestamp":1771805849,"startTime":"0","endTime":"0","summary":"基石药业-B(02616)发布公告，舒格利单抗的新适应症申请已获英国药品和医疗保健用品管理局(MHRA)批准单药用于治疗肿瘤细胞PD-L1表达≥1%、无表皮生长因数受体(EGFR)敏感突变或ALK、ROS1基因组变异、在含铂放化疗(CRT)后未出现疾病进展的、不可切除的III期小细胞肺癌(NSCLC)成人患者。","market":"us","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_48.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_48.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1406210.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["02616","BK1161","III","BK4134","BK1574"],"gpt_icon":0},{"id":"2611713190","title":"倍择瑞®治疗未控制哮喘的KALOS与LOGOS III期试验取得具有临床意义的阳性结果 相关成果发表于《柳叶刀-呼吸病学杂志》","url":"https://stock-news.laohu8.com/highlight/detail?id=2611713190","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611713190?lang=zh_cn&edition=full","pubTime":"2026-02-13 15:43","pubTimestamp":1770968580,"startTime":"0","endTime":"0","summary":"完整结果可查阅《柳叶刀-呼吸病学杂志》。KALOS与LOGOS试验表明，布地格福固定三联吸入疗法能够同时发挥ICS、LAMA和LABA的疗效，改善肺功能。KALOS与LOGOS研究结果有力地证实，布地格福固定三联吸入疗法有望为该类型哮喘患者带来健康获益。\" 在KALOS与LOGOS试验中，布地格福吸入气雾剂未出现新的安全性或耐受性问题。KALOS与LOGOS研究共纳入约4300名随机分组患者。KALOS和LOGOS试验的主要终点和治疗比较方案因监管申报途径的不同而有所差异。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4887756_ZH87756_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4568","LU2456880835.USD","AZN","III","LU2236285917.USD","LU0109394709.USD","LU0289739699.SGD","BK4585","LU2462157665.USD","LU1829250122.USD","BK4588","LU0889565916.HKD","LU2417539215.USD","LU0058720904.USD","BK4134","BK4007","LU0320765992.SGD"],"gpt_icon":0},{"id":"2610699154","title":"中国生物制药(01177)升5% TQB2102 III期临床完成入组 此前Ib期ASCO数据良好","url":"https://stock-news.laohu8.com/highlight/detail?id=2610699154","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610699154?lang=zh_cn&edition=full","pubTime":"2026-02-10 10:52","pubTimestamp":1770691959,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中国生物制药(01177)短线拉高，截止发稿， 升5.15%，报6.94港元，成交额1.94亿港元。公司公告公布，集团自主研发的国家1类创新药TQB2102“HER2双抗ADC”正在开展一项“评价注射用TQB2102对比研究者选择的化疗在HER2低表达复发╱转移性乳腺癌中有效性和安全性的随机、开放、平行对照的III期临床试验(TQB2102-III-01)”，近期已完成全部受试者入组。在2025年美国临床肿瘤学会(ASCO)年会上，集团公布了TQB2102用于HER2低表达晚期乳腺癌的 Ib期临床研究结果，显示出良好的疗效与安全性。","market":"hk","thumbnail":"https://static.szfiu.com/news/20241108/ODBhOTU0MzI3NjMwOTM5MjE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/ODBhOTU0MzI3NjMwOTM5MjE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1974849","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000165453.HKD","01177","IE00BZ08YR35.GBP","BK1191","IE00BZ08YT58.USD","BK1515","BK1589","IE00BZ08YS42.EUR","BK1521","III","BK4134"],"gpt_icon":0},{"id":"2610661036","title":"中国生物制药(01177)：TQB2102“HER2双抗ADC”HER2低表达乳腺癌III期临床试验完成受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2610661036","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610661036?lang=zh_cn&edition=full","pubTime":"2026-02-10 06:16","pubTimestamp":1770675411,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药 发布公告，集团自主研发的国家1类创新药TQB2102“HER2双抗ADC”正在开展一项“评价注射用TQB2102对比研究者选择的化疗在HER2低表达复发╱转移性乳腺癌中有效性和安全性的随机、开放、平行对照的III期临床试验”，近期已完成全部受试者入组。以上核心技术的结合，突破了传统HER2单抗及单靶点ADC的局限，使TQB2102在HER2低表达肿瘤治疗中展现出显著潜力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1403406.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4080","ADC","HK0000165453.HKD","BK4231","BK1515","BK4134","BK1191","IE00BZ08YT58.USD","IE00BZ08YS42.EUR","BK1589","III","01177","BK1521","IE00BZ08YR35.GBP"],"gpt_icon":0},{"id":"2610503880","title":"中国生物制药(01177)：维特柯妥拜单抗“CLDN18.2 ADC”III期临床试验完成受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2610503880","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610503880?lang=zh_cn&edition=full","pubTime":"2026-02-09 06:15","pubTimestamp":1770588951,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药 发布公告，集团全资附属公司礼新医药科技(上海)有限公司自主研发的国家1类创新药维特柯妥拜单抗“CLDN18.2 ADC”正在开展用于治疗三线及以上CLDN18.2阳性的局部晚期或转移性胃及胃食管交界部腺癌的III期注册临床试验，已顺利完成患者入组。其中，LM302是全球首款完成注册III期临床试验入组的CLDN18.2 ADC药物。该研究表明，LM302联合治疗方案在CLDN18.2阳性患者中展现出显著的抗肿瘤活性和可管理的安全性特征。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1402910.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4080","HK0000165453.HKD","BK4231","01177","IE00BZ08YR35.GBP","BK1191","IE00BZ08YT58.USD","BK1515","BK1589","IE00BZ08YS42.EUR","ADC","BK1521","III","BK4134"],"gpt_icon":0},{"id":"2609321873","title":"AI生物科技公司Generate(GENB.US)拟赴美IPO募资1亿美元 核心哮喘疗法已进入III期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2609321873","media":"智通财经网","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609321873?lang=zh_cn&edition=full","pubTime":"2026-02-05 14:52","pubTimestamp":1770274343,"startTime":"0","endTime":"0","summary":"专注于哮喘治疗的AI生物科技公司Generate Biomedicines(GENB.US)周三向美国证券交易委员会提交文件，计划通过首次公开募股筹集至多1亿美元。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20260205/20260205145238_12198.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260205/20260205145238_12198.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401992.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK4585","BK4134","III","159837","LABU","BK4588"],"gpt_icon":0},{"id":"2608359175","title":"广生堂(300436.SZ)：奈瑞可韦GST-HG141完成III期临床试验受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2608359175","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608359175?lang=zh_cn&edition=full","pubTime":"2026-02-04 16:43","pubTimestamp":1770194609,"startTime":"0","endTime":"0","summary":"智通财经APP讯，广生堂(300436.SZ)公告，公司创新药控股子公司福建广生中霖生物科技有限公司的在研乙肝治疗一类创新药奈瑞可韦GST-HG141的III期临床试验，已于近日完成全部受试者入组，合计入组578例。本次GST-HG141完成III期临床试验全部受试者入组后，尚需按照已制定临床方案和要求继续推进临床试验，并经国家药品审评部门注册审批通过后方可上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401558.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","III","300436","GST","BK4134"],"gpt_icon":0},{"id":"2608289128","title":"卓创资讯：大宗商品价格波动加剧提升市场对专业信息服务的需求","url":"https://stock-news.laohu8.com/highlight/detail?id=2608289128","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608289128?lang=zh_cn&edition=full","pubTime":"2026-02-03 15:44","pubTimestamp":1770104687,"startTime":"0","endTime":"0","summary":"证券之星消息，卓创资讯 02月03日在投资者关系平台上答复投资者关心的问题。卓创资讯作为国内领先的大宗商品信息服务企业，始终专注于市场数据监测、价格评估及行业分析。当前大宗商品及贵金属价格波动加剧，客观上提升了市场对专业信息服务的需求，尤其可能吸引更多金融机构等非产业客户。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260203/31994528.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["301299","BK0231","161715","BK4134","000979.SH","III"],"gpt_icon":0},{"id":"2608694859","title":"软件和信息服务业成江苏南京首个万亿级产业集群","url":"https://stock-news.laohu8.com/highlight/detail?id=2608694859","media":"中国新闻网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608694859?lang=zh_cn&edition=full","pubTime":"2026-02-02 16:22","pubTimestamp":1770020520,"startTime":"0","endTime":"0","summary":"中新社南京2月2日电 南京市工业和信息化局2日发布消息，根据中国工业和信息化部软件业运行快报，江苏南京2025年软件业务收入规模约为10200亿元，同比增长16.7%。由此，软件和信息服务业成为南京首个万亿级产业集群。早在2001年，南京出台了软件和信息服务业发展专项政策，系统布局发展软件产业。据统计，2025年南京入库人工智能(软件)招商项目326个，其中投资额亿元以上项目90个、高能级项目21个。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-02-02/doc-inhkmfsh8088853.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-02-02/doc-inhkmfsh8088853.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["III","BK4134"],"gpt_icon":0},{"id":"2608880406","title":"诺诚健华新型TYK2抑制剂ICP-488治疗银屑病的III期临床试验完成患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2608880406","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608880406?lang=zh_cn&edition=full","pubTime":"2026-02-02 08:50","pubTimestamp":1769993437,"startTime":"0","endTime":"0","summary":"每经AI快讯，2月2日，诺诚健华官微宣布，公司自主研发的新型TYK2抑制剂ICP-488治疗银屑病的III期临床试验已完成患者入组，总共入组383例患者。这一里程碑标志着ICP-488治疗银屑病取得重大临床进展，有望为银屑病患者带来新的口服治疗选择。这项临床试验为多中心、随机、双盲、安慰剂对照，旨在评价ICP-488单药治疗中重度斑块状银屑病成人患者的有效性和安全性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602023638037294.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602023638037294.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["III","688428","BK1574","09969","BK1161","BK0239","BK4134"],"gpt_icon":0},{"id":"2607790083","title":"歌礼制药-B(01672)：同类首创每日一次口服FASN抑制剂地尼法司他(ASC40)治疗痤疮的III期开放标签研究取得积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2607790083","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607790083?lang=zh_cn&edition=full","pubTime":"2026-01-29 18:56","pubTimestamp":1769684198,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B 发布公告，同类首创、每日一次口服小分子脂肪酸合成酶抑制剂地尼法司他在中重度寻常性痤疮患者中的III期开放标签研究取得积极顶线结果。这240例患者均接受了40周的每日一次地尼法司他治疗，且此前均接受过12周的地尼法司他或安慰剂治疗。地尼法司他 显示出良好的安全性和耐受性特征。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1399288.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01672","BK1191","III","BK1515","BK4134","01477","BK1161","BK1574"],"gpt_icon":0},{"id":"2605316104","title":"新股消息 | 普祺医药递表港交所 核心产品普美昔替尼凝胶已完成III期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2605316104","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605316104?lang=zh_cn&edition=full","pubTime":"2026-01-22 07:20","pubTimestamp":1769037657,"startTime":"0","endTime":"0","summary":"普美昔替尼凝胶：全球首款用于治疗特应性皮炎的JAK抑制剂凝胶，公司已就其完成成人及12至17岁青少年特应性皮炎适应症的III期临床试验，有待提交新药上市申请。普美昔替尼鼻喷雾剂：全球首款用于治疗季节性过敏性鼻炎的临床阶段JAK抑制剂鼻喷雾剂，现正处于针对成年人SAR适应症的III期临床试验阶段。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1395906.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["III","159938","BK1574","BK1161","BK1515","09939","BK4134","HEXmain"],"gpt_icon":0},{"id":"2605435278","title":"百时美施贵宝 (BMS) CAR-T疗法启动III期临床，治疗自免疾病","url":"https://stock-news.laohu8.com/highlight/detail?id=2605435278","media":"细胞治疗前沿","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605435278?lang=zh_cn&edition=full","pubTime":"2026-01-21 09:53","pubTimestamp":1768960424,"startTime":"0","endTime":"0","summary":"近日，美国临床试验收录网显示，百时美施贵宝的 CD19 CAR-T 细胞疗法 Zola-cel启动了首个 Ⅲ 期临床试验，治疗活动性系统性硬化症。Zola-cel是BMS基于NEX-T平台开发的一款CD19 CAR-T细胞疗法，于2020年进入临床阶段。2019年，BMS以740亿美元完成对Celgene的收购，借此将两款关键CAR-T疗法Breyanzi与Abecma纳入其产品管线，正式踏入细胞治疗领域。BMS积极布局，不断强化其在下一代细胞治疗领域的战略纵深。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026012110365897a2adbb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026012110365897a2adbb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0868494617.USD","BMS","LU2133065610.SGD","LU0882574055.USD","LU0096364046.USD","III","IE00BJJMRZ35.SGD","LU0225284248.USD","BK4588","LU0061475181.USD","LU2125154935.USD","LU1571399168.USD","LU2360032135.SGD","LU0321505439.SGD","IE00BFTCPJ56.SGD","IE00BSNM7G36.USD","IE00BJT1NW94.SGD","LU1718418525.SGD","LU1868836591.USD","LU1032466523.USD","IE00BFXG1179.USD","BK4007","LU1670711123.USD","LU0306806265.USD","LU2125154778.USD","CAR","LU0321505868.SGD","BMY","LU1670710661.SGD","BK4585","LU1868836914.USD","BK4534","LU1670711040.USD","LU1261432733.SGD","BK4532","LU0267386448.USD","LU0225771236.USD","LU2242652126.USD","LU0114720955.EUR","LU0306807586.USD","LU1868836757.USD","LU1868837136.USD","BK4581","LU1323610961.USD","BK4559","LU1291159041.SGD","LU0985481810.HKD","IE0002141913.USD","LU1989771016.USD","BK4134"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.isg-one.com","stockEarnings":[{"period":"1week","weight":0.0258},{"period":"1month","weight":-0.1687},{"period":"3month","weight":-0.1115},{"period":"6month","weight":-0.0754},{"period":"1year","weight":0.537},{"period":"ytd","weight":-0.173}],"compareEarnings":[{"period":"1week","weight":0.007},{"period":"1month","weight":-0.0089},{"period":"3month","weight":0.0086},{"period":"6month","weight":0.0686},{"period":"1year","weight":0.1594},{"period":"ytd","weight":0.0108}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Information Services Group, Inc.于2006年7月20日在特拉华州注册成立。该公司是一家全球领先的技术研究和咨询公司。ISG是超过900家客户、超过75家百强企业值得信赖的商业伙伴，致力于帮助企业、公共部门组织以及服务和技术提供商实现卓越运营和更快增长。该公司专门从事数字化转型服务，包括自动化、云和数据分析；采购咨询；托管治理和风险服务；网络载体服务；技术战略和运营设计；变革管理；市场情报和技术研究与分析。","yearOnYearQuotes":[{"month":1,"riseRate":0.444444,"avgChangeRate":0.022101},{"month":2,"riseRate":0.5,"avgChangeRate":0.004342},{"month":3,"riseRate":0.333333,"avgChangeRate":0.043359},{"month":4,"riseRate":0.444444,"avgChangeRate":-0.008159},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.028576},{"month":6,"riseRate":0.5,"avgChangeRate":0.015439},{"month":7,"riseRate":0.444444,"avgChangeRate":0.01427},{"month":8,"riseRate":0.555556,"avgChangeRate":0.010481},{"month":9,"riseRate":0.444444,"avgChangeRate":-0.004212},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.036611},{"month":11,"riseRate":0.611111,"avgChangeRate":0.053419},{"month":12,"riseRate":0.555556,"avgChangeRate":0.003262}],"exchange":"NASDAQ","name":"信息服务","nameEN":"Information"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"信息服务(III)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供信息服务(III)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"信息服务,III,信息服务股票,信息服务股票老虎,信息服务股票老虎国际,信息服务行情,信息服务股票行情,信息服务股价,信息服务股市,信息服务股票价格,信息服务股票交易,信息服务股票购买,信息服务股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"信息服务(III)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供信息服务(III)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}